These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 12433062)
1. Implications of the new FDA/CDER immunotoxicology guidance for drugs. Hastings KL; Int Immunopharmacol; 2002 Oct; 2(11):1613-8. PubMed ID: 12433062 [TBL] [Abstract][Full Text] [Related]
2. Immunotoxicology: role in the safety assessment of drugs. Descotes J Drug Saf; 2005; 28(2):127-36. PubMed ID: 15691223 [TBL] [Abstract][Full Text] [Related]
3. US FDA "Redbook II" immunotoxicity testing guidelines and research in immunotoxicity evaluations of food chemicals and new food proteins. Hinton DM Toxicol Pathol; 2000; 28(3):467-78. PubMed ID: 10862567 [TBL] [Abstract][Full Text] [Related]
4. The identification of chemicals with sensitizing or immunosuppressive properties in routine toxicology. Basketter DA; Bremmer JN; Kammuller ME; Kawabata T; Kimber I; Loveless SE; Magda S; Pal TH; Stringer DA; Vohr HW Food Chem Toxicol; 1994 Mar; 32(3):289-96. PubMed ID: 8157225 [TBL] [Abstract][Full Text] [Related]
5. Regulatory immunotoxicology: does the published evidence support mandatory nonclinical immune function screening in drug development? Snodin DJ Regul Toxicol Pharmacol; 2004 Dec; 40(3):336-55. PubMed ID: 15546688 [TBL] [Abstract][Full Text] [Related]
6. Toxicity of excipients--a Food and Drug Administration perspective. Osterberg RE; See NA Int J Toxicol; 2003; 22(5):377-80. PubMed ID: 14555410 [TBL] [Abstract][Full Text] [Related]
7. Assessing immunotoxicity: guidelines. Putman E; van der Laan JW; van Loveren H Fundam Clin Pharmacol; 2003 Oct; 17(5):615-26. PubMed ID: 14703723 [TBL] [Abstract][Full Text] [Related]
9. What are the prospects for regulation in immunotoxicology? Hastings KL Toxicol Lett; 1998 Dec; 102-103():267-70. PubMed ID: 10022264 [TBL] [Abstract][Full Text] [Related]
10. An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs). Avila AM; Bebenek I; Bonzo JA; Bourcier T; Davis Bruno KL; Carlson DB; Dubinion J; Elayan I; Harrouk W; Lee SL; Mendrick DL; Merrill JC; Peretz J; Place E; Saulnier M; Wange RL; Yao J; Zhao D; Brown PC Regul Toxicol Pharmacol; 2020 Jul; 114():104662. PubMed ID: 32325112 [TBL] [Abstract][Full Text] [Related]
11. The ICH S8 immunotoxicity guidance. Immune function assessment and toxicological pathology: autonomous or synergistic methods to predict immunotoxicity? Spanhaak S Exp Toxicol Pathol; 2006 Jul; 57(5-6):373-6. PubMed ID: 16723215 [TBL] [Abstract][Full Text] [Related]
13. Importance of immunotoxicity in safety assessment: a medical toxicologist's perspective. Descotes J Toxicol Lett; 2004 Apr; 149(1-3):103-8. PubMed ID: 15093254 [TBL] [Abstract][Full Text] [Related]
14. International Conference on Harmonisation; Guidance on S8 Immunotoxicity Studies for Human Pharmaceuticals; availability. Notice. Food and Drug Administration, HHS Fed Regist; 2006 Apr; 71(71):19193-4. PubMed ID: 16612859 [TBL] [Abstract][Full Text] [Related]
15. Clinical immunotoxicity of therapeutic proteins. Descotes J; Gouraud A Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1537-49. PubMed ID: 19040329 [TBL] [Abstract][Full Text] [Related]
16. Prospects for developmental immunotoxicity guidance and an update on ICH S8. Hastings KL J Immunotoxicol; 2005 Oct; 2(4):217-20. PubMed ID: 18958677 [TBL] [Abstract][Full Text] [Related]
17. Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls. Giannakou C; Park MVDZ; Bosselaers IEM; de Jong WH; van der Laan JW; van Loveren H; Vandebriel RJ; Geertsma RE Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Sep; 12(5):e1633. PubMed ID: 32266791 [TBL] [Abstract][Full Text] [Related]